BioSpace News Archive

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that five oral presentations and two on-demand papers are being highlighted at the American Society of Retina Specialists Annual Scientific Meeting taking place July 13 -16, 2022 in New York City.

Creative Bio-Peptides, Inc, a preclinical-stage biotechnology company developing novel therapies to balance the innate immune system and promote regeneration of damaged neurons, today announced the publication of findings from a preclinical study showing that treatment with the small oral peptide chemokine receptor antagonist RAP-103.

The global non-steroidal anti-inflammatory drugs market was surpassed at USD 19,551.54 million in 2021 and is expected to hit around USD 31.45 billion by 2030, growing at a CAGR of 5.42% from 2022 to 2030.

The global orthokeratology lens market size was estimated at around USD 611.6 million in 2021 and it is projected to hit around USD 1.12 billion by 2030, growing at a CAGR of 6.95% from 2022 to 2030.

Today, Health Canada authorized the use of the Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age.

SPR Therapeutics announced today that two presentations highlighting SPRINT® PNS in treating chronic pain will be featured at the American Society of Pain & Neuroscience (ASPN) conference July 14-17.

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 second quarter financial results before the opening of the market on July 21, 2022.

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced it is among the first group of companies worldwide to receive approval of its net-zero targets by the Science Based Targets initiative.

BeiGene, a global oncology biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced that the U.S. Food and Drug Administration has deferred action on the Biologics License Application for tislelizumab as a second-line treatment for patients with unresectable or metastatic esophageal squamous cell carcinoma.

Abiomed, Inc . (NASDAQ: ABMD) announced that on Thursday, August 4, 2022, the Company will release financial results for the first quarter of the fiscal year 2023.